Yuhan Corporation(61,500 0.00%)Announced on the 23rd that it has invested an additional 10 billion won in April Bio. Accordingly, it became the second largest shareholder.
Established in 2013, April Bio has a human antibody library (HuDVFab) technology and’SAFA (Serum Albumin Fragment Associated)’, a sustained platform technology that can increase half-life using antibody fragmentation. Through this, it is an antibody company that develops innovative new drugs.
April Bio is preparing for phase 1 clinical trial in the United States this year,’APB-A1′, an autoimmune disease treatment (targeting CD40L),’APB-R3′, a preclinical inflammatory autoimmune disease treatment (IL-18), and male infertility treatment (FSH). )’APB-R2′, etc. are being developed.
Recently, April Bio decided to issue a paid-in capital increase of 10 billion won worth to a third party for Yuhan Corporation. Last year, it attracted 18 billion won worth of’Series B’investment. At that time, Yuhan Corporation also invested 3 billion won as a strategic investor (SI) to acquire a 4.89% stake. Since then, Yuhan Corporation and April Bio have signed a business agreement to develop new drugs for joint research and are strengthening research cooperation.
April Bio is preparing for a special listing through technology evaluation this year. Major financial investors are LB Investment and TS Investment(4,650 -4.52%) Such as Hana Financial Investment.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution